Clinical Trials Logo

Filter by:
NCT ID: NCT06205459 Recruiting - Deep Caries Clinical Trials

Deep Marginal Acquisition With Thermacut Bur Vs. Functional Crown Lengthening in Deep Carious Lesions

Start date: February 2, 2024
Phase: N/A
Study type: Interventional

this clinical trial is conducted to compare between deep marginal acquistion by the means of thermacut bur Vs. functional crown lengthening in exposing deep subgingival interproximal cervical lesions

NCT ID: NCT06205420 Recruiting - Enamel Hypoplasia Clinical Trials

Injection Molding Technique: A Minimally Invasive Management for Enamel Hypoplasia Affecting Permanent Anterior Teeth in Children

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

This study aims to evaluate and compare the clinical performance of the injectable giomer restoration versus an injectable composite resin restoration using the injection molding technique for veneering hypoplastic permanent maxillary and mandibular anterior teeth using the FDI criteria. Follow up will be done every 6 months for 2 years.

NCT ID: NCT06202755 Recruiting - Ischemic Stroke Clinical Trials

Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke

Start date: December 12, 2022
Phase: Phase 3
Study type: Interventional

Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever large-vessel ischemic stroke compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.

NCT ID: NCT06202365 Recruiting - Obesity Clinical Trials

Whole Body Vibration in Obese Female Students

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

Obesity is a global public-health issue, with rising incidence and prevalence, significant expenditures, and poor results. Obesity has become a worldwide epidemic in both developed and underdeveloped countries. A body mass index (BMI) of 30 kg/m2 is required for class I obesity, a BMI of 35 - 39.9 kg/m2 is required for class II obesity, and a BMI of 40 kg/m2 is required for class III obesity (morbidly obese). Obesity will be the likely situation for the majority of the adult population during the next two decades due to an abundance of calorie-rich food and apathy toward exercise.

NCT ID: NCT06201793 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Minocyclin in Ulcerative Colitis as Added on Therapy

Start date: January 22, 2024
Phase: Phase 2
Study type: Interventional

Ulcerative colitis (UC) is considered a subcategory of inflammatory bowel disease and the exact cause of ulcerative colitis remains undetermined. the condition appears to be related dysregulated immune response and consequent activation of inflammatory cascades, which are often affected by genetic susceptibility and environmental factors, and 20% to 40% of patients with UC also exhibit extraintestinal manifestations involving the joints, skin, eyes, or hepatobiliary tract

NCT ID: NCT06201780 Recruiting - Clinical trials for Cholinergic Urticaria

Assessment of Serum Levels of Janus Kinase 1 and 2 in Patients With Cholinergic Urticaria

Start date: December 15, 2023
Phase: N/A
Study type: Interventional

Cholinergic Urticaria (CholU) is as a subtype of CIndU caused by an increase in the core body temperature, such as to activate the sweating reflex. It can occur in response to physical exercise, hot bathing and/or emotional stress. Clinically it appears as pinpointing and highly pruritic wheals with surrounding erythema, CholU can be accompanied by severe symptoms such as angioedema, respiratory symptoms or anaphylaxi CholU is frequently associated with atopic dermatitis (AD) The JAK-STAT is a mast cell (MC) signaling pathway activated downstream of IgE and IL-3 with important roles in MC homeostasis via regulation of proliferation, survival, and release of mediators. JAK-STAT activation is associated with polarization toward Th2, B cell isotype switching to IgE production, and IgE-dependent degranulation and cytokine release . Because both IL-4 and IL-13 use the IL-4Rα as a receptor component, these cytokines activate any common signaling pathways. Both of these cytokines use Janus kinases (JAKs) to initiate signaling and activate signal transducer and activator of transcription-6 (STAT6), which is a transcription factor required for many of their biologic functions. The non-receptor protein tyrosine kinases JAK1 and JAK3 associate with the IL-4Rα and γC, respectively. The binding of IL-4 to its receptor induces the transphosphorylation of JAK1 and JAK3, an event that activates these kinases and thereby initiates the early events of signal transduction .

NCT ID: NCT06201663 Recruiting - Clinical trials for Chemotherapy-induced Thrombocytopenia

Romiplostim in Chemotherapy-Induced Thrombocytopenia

Start date: December 17, 2023
Phase: Phase 3
Study type: Interventional

Prospective interventional randomized controlled trial to assess safety and efficacy of romiplostim in chemotherapy-induced thrombocytopenia in children and adolescents with solid malignancy

NCT ID: NCT06201624 Recruiting - Melasma Clinical Trials

Oral Isotretinoin in Melasma a Randomized Controlled Trial

Start date: March 1, 2023
Phase: Phase 1
Study type: Interventional

Melasma is a common refractory acquired hyperpigmentation of the skin having a serious impact on patients' quality of life. Melasma is challenging to treat. Treatment is often a multimodality approach. Due to the attached psychological and social stress, it is important to counsel patients with melasma adequately about the chronicity of the disease, the importance of photoprotection, and the role of hormones in disease persistence before embarking on therapeutic correction. So in this study, we are exploring the efficacy of oral isotretinoin for treating melasma.

NCT ID: NCT06200701 Recruiting - Nurse's Role Clinical Trials

Intervention Program of a Job Crafting

JobCrafting
Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The implementation of effective intervention programs is crucial in enhancing the overall well-being and performance of healthcare professionals, particularly in demanding environments such as nursing

NCT ID: NCT06200090 Recruiting - Burnout Clinical Trials

Empathy and Emotional Regulation: A Multi-National Cross-Sectional Study

Start date: April 15, 2023
Phase:
Study type: Observational

Significant levels of psychological disorders and psychological distress among higher education students have been reported worldwide (Galdino et al., 2020), given that during these years there is a peak in prevalence of many mental disorders, particularly major depressive disorder (18.5% to 21.2%), generalized anxiety disorder (18.6% to 16.7%) and drug use disorder (45.9% to 59.8%). (Auerbach et al., 2018). Additionally, compared to other major students, medical school and nursing students experienced higher levels of burnout due to the complex curriculum and pressure for professional performance (Ling et al., 2014). Altogether, this evidence show that nursing students frequently experience psychological and emotional problems such as academic exhaustion, stress, depression, and anxiety during their four years of completing their degree (Hwang & Kim, 2022). To the best of our knowledge, this study is the first of its kind that addresses the issue of burnout and its relation to empathy and emotional regulation among nursing students at the middle east. Analyzing burnout syndrome among undergraduate nursing students may provide support for managers to implement prevention and management strategies in relation to the syndrome, in order to ensure health and well-being during the professional training process, as well as providing training for nurses engaged and prepared to provide quality care. Thus, this study aims to investigate the burnout syndrome among nursing students and its relation to empathy and emotional regulation.